IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer

The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2–3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chengliang, Gan, Gregory N., Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275499/
https://www.ncbi.nlm.nih.gov/pubmed/32503595
http://dx.doi.org/10.1186/s13045-020-00898-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275499/
https://www.ncbi.nlm.nih.gov/pubmed/32503595
http://dx.doi.org/10.1186/s13045-020-00898-y

Ejemplares similares